- Home
- FRME vs VERA Comparison
FRME vs VERA Comparison
Compare FRME & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRME
- VERA
- Stock Information
- Founded
- FRME 1893
- VERA 2016
- Country
- FRME United States
- VERA United States
- Employees
- FRME N/A
- VERA N/A
- Industry
- FRME Major Banks
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- FRME Finance
- VERA Health Care
- Exchange
- FRME Nasdaq
- VERA Nasdaq
- Market Cap
- FRME 2.1B
- VERA 2.5B
- IPO Year
- FRME N/A
- VERA 2021
- Fundamental
- Price
- FRME $37.96
- VERA $42.01
- Analyst Decision
- FRME Buy
- VERA Strong Buy
- Analyst Count
- FRME 5
- VERA 9
- Target Price
- FRME $43.90
- VERA $53.56
- AVG Volume (30 Days)
- FRME 248.8K
- VERA 683.6K
- Earning Date
- FRME 10-24-2024
- VERA 11-07-2024
- Dividend Yield
- FRME 3.78%
- VERA N/A
- EPS Growth
- FRME N/A
- VERA N/A
- EPS
- FRME 3.01
- VERA N/A
- Revenue
- FRME $593,089,000.00
- VERA N/A
- Revenue This Year
- FRME N/A
- VERA N/A
- Revenue Next Year
- FRME $3.02
- VERA N/A
- P/E Ratio
- FRME $12.35
- VERA N/A
- Revenue Growth
- FRME N/A
- VERA N/A
- 52 Week Low
- FRME $26.85
- VERA $9.68
- 52 Week High
- FRME $42.45
- VERA $50.78
- Technical
- Relative Strength Index (RSI)
- FRME 53.37
- VERA 52.57
- Support Level
- FRME $35.13
- VERA $39.22
- Resistance Level
- FRME $37.35
- VERA $50.00
- Average True Range (ATR)
- FRME 1.17
- VERA 2.41
- MACD
- FRME -0.06
- VERA 0.24
- Stochastic Oscillator
- FRME 54.14
- VERA 28.53
About FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.